Rajiv Gandhi University of Health Sciences
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES, KARNATAKA
4th ‘T’ Block, Jayanagar, Bangalore - 560 041
ANNEXURE – II
PROFORMA FOR REGISTRATION OF SUBJECTS FOR DISSERTATION
| | | |
|1.0 |Name of the Candidate |Binish Khan |
| |and Address: | |
| | |D-194,Okhla,Abul Fazal Enclave, |
| | |New Delhi-110025 |
| | | |
|2.0 |Name of the Institution: |Al-Ameen College of Pharmacy, |
| | |Hosur Road, Bangalore – 560 027. |
| | | |
| | | |
|3.0 |Course of Study and Subject: |M. Pharm – Pharmaceutics |
| | | |
| | | |
| | | |
|4.0 |Date of Admission: |November – 2011 |
| | | |
| | |
| | |
|5.0 |Title of the Topic: |
| |“Design and Evaluation of mucoadhesive antifungal vaginal hydrogel of miconazole nitrate for candidiasis” |
| | |
|6.0 |Brief resume of the intended work: |
| | |
| | |
| |– Need for the study: |
| |Vaginitis is the inflammation of the vagina which can result in discharge, itching, pain and often an irritation or infection of the vulva. The |
| |three main kinds of vaginitis are: bacterial vaginosis (BV), vaginal candidiasis and trichomoniasis. Candidiasis or thrush is a fungal infection |
| |(mycosis) of any of the Candida species (all yeasts), of which Candida albicans is most common. It is a yeast infection and is also known |
| |as candidosis, moniliasis, andoidiomycosis1. |
| |Candidiasis infects the mouth, vagina, skin, stomach, and urinary tract. About 75% of women get a vaginal yeast infection during their lifetime, |
| |and 90% of all people with HIV/AIDS develop candida infection. If it grows excessively from colon and vagina it penetrates the lining of the |
| |colon and spreads into the bladder, vagina, small intestine, blood, lymph, brain, lung and other areas of the body2. Symptoms are body aches and |
| |pains, fatigue, athlete’s foot, diarrhea, bloating, vaginal infections, skin rashes, patches, and blisters in the groin, between fingers and |
| |toes, and under the breasts, vaginal itching and irritation with a white discharge resembling cottage cheese2,3. It is estimated that 1/3rd of |
| |the population is suffering from candida albicans overgrowth2. |
| |The goals of pharmacotherapy in vaginitis are to reduce morbidity, prevent complications, and eradicate the infection. Drugs used for infectious |
| |causes of vaginitis may be applied topically or may require oral or parenteral administration. |
| |The antifungal agents used to treat vaginitis are imidazole derivatives that exert a fungicidal effect by altering permeability of the fungal |
| |cell membrane. The mechanism of action also may involve alteration of RNA and DNA metabolism or an intracellular accumulation of peroxides toxic |
| |to fungal cell. Intravaginal and topical therapy with a variety of antifungals (eg, clotrimazole, miconazole, terconazole, tioconazole) is highly|
| |effective. |
| |Miconazole is an anti-fungal medication used either on the skin or in the vagina for fungal infections. It prevents fungal organisms from |
| |producing vital substances required for growth and function. It interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert |
| |lanosterol to ergosterol. Ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis increases cellular |
| |permeability causing leakage of cellular contents. Miconazole exhibits half life of 24.1 hours and has poor water solubility. The common dosage |
| |is 5 - 10 g for 7 to 14 days or 100 mg twice a day for 5 days4. |
| |For vaginal yeast infections, medications available over the counter include creams and suppositories. Most treatments last from 2 - 3 days to 2 |
| |weeks3,5 . The main disadvantages of vaginal suppository are that it is less patient complaint, mucosal irritation and erratic and undesired |
| |absorbtion6. Creams and ointments are messy, uncomfortable and leak out of the vagina. Thus there is need to develop better dosage forms for |
| |antifungals used in the treatment of vaginitis. |
| |Gels are semi-solid, three-dimensional, polymeric matrices comprising small amounts of solid, dispersed in relatively large amounts of liquid, |
| |yet possessing more solid-like character7. Gels that contain water are called hydrogels, while that containing an organic liquid are called |
| |organogels. Hydrogels include the matrix of water - soluble materials such as cellulose derivatives and natural gums. Mucoadhesive polymers of |
| |natural, semisynthetic or synthetic origin are able to form hydrogels8,9. Mucoadhesion is the attachment of the drug along with a suitable |
| |carrier to the mucous membrane. When drug particles are directly dispersed in mucoadhesive gel, the mucoadhesive polymer will be absorbed onto |
| |the particle surface and the contact time of drug particles with mucous membranes will further increase10. |
| | |
| |Vaginal gels optimize safety, efficacy and acceptability. They possess a higher biocompatibility and bioadhesivity and can be rapidly |
| |eliminated through normal catabolic pathways which decreases the risk for irritative or allergic host reaction at the application |
| |site.9. |
| | |
| |Mucoadhesive gel prepared by bioadhesive polymer has the property of increasing the time of retention. The disadvantage of the drug of poor water|
| |solubility can be improved by formulating the drug to a gel of mucoadhesive polymers as well as permeation enhancer. Bioadhesive polymer and |
| |permeation enhancer increases the time of contact and permeation which increases the bioavaibility, reduces dosing frequency and causes fast |
| |onset of action11,12,13,14,15 |
| | |
| |In the present research work an attempt will be made to formulate, optimize and evaluate antifungal vaginal hydrogel of miconazole by using |
| |mucoadhesive polymers. Such a gel is proposed to increase the adhesion time of the drug at the site of application and hence might increase the |
| |permeation and bioavailabilty of the drug. |
| | |
| | |
| | |
| | |
| | |
| | |
| |6.2 REVIEW OF LITERATURE |
| |J. das Neves et al., (2006) studied the vaginal anatomy histology, physiology and discussed about gels as vaginal drug delivery systems. They did|
| |pharmaceutical characterization of vaginal gels by evaluation of drug release and permeation studies, by doing mechanical studies on it, by |
| |toxicological evaluation, mucoadhesion and vaginal retension and distribution. They also discussed about the excipients used in gels. Discussed |
| |about clinical usage and potential of vaginal gels. Summarized acceptability of gels for vaginal administration and concluded that although most |
| |of the times regarded as an alternative to more conventional routes of drug delivery, vaginal drug administration has proven to be useful and |
| |even advantageous in some particular cases. In these review they summarized the continuing interest, and discussed the current research in this |
| |field 7. |
| | |
| |Krishna S el al., (2012) provided a review article on vagina as drug delivery system. In the article they discussed various polymers which are |
| |used in hydrogel which provide bioadhesive property to the vaginal formulations, so that the formulation remains vaginal tissues for proper time.|
| |The main objective of the review was to summarize various vaginal drug delivery systems with an special emphasis an vaginal physiology, factors |
| |affecting the vaginal drug absorption, mechanism of vaginal epithelium drug absorption including the advances in the current approaches in |
| |vaginal drug delivery systems. The article also gave the advantages of vaginal drug delivery system and a summary on classification of |
| |intravaginal drug delivery systems8. |
| | |
| |Amit A et al., (2011) presented a review describing mucoadhesion, mucoadhesive polymers, uses of these polymers in designing different types of |
| |mucoadhesive drug delivery systems, permeation enhancers, types and their properties. The review explained that the mucoadhesive systems remain |
| |in close contact with the absorption tissue, the mucous membrane, releasing the drug at the site of action leading to increase in bioavailability|
| |(both local and systemic effects). Extending the residence time of a dosage form at a particular site and controlling the release of drug from |
| |the dosage form are useful especially for achieving controlled plasma level of the drug as well as improving bioavailability. Mucoadhesive |
| |polymers are water-soluble and water insoluble polymers, which have swellable networks, jointed by cross-linking agents. These polymers possess |
| |optimal polarity to make sure that they permit sufficient wetting by the mucous and optimal fluidity that permits the mutual adsorption and |
| |interpenetration of polymer and mucous takes place12. |
| |Noha A. N. et al., (2002) evaluated mucoadhesive patches containing 10 mg miconazole nitrate. They prepared the patches with ionic polymers, |
| |sodium carboxymethyl cellulose (SCMC) and chitosan, or non-ionic polymers, polyvinyl alcohol (PVA), hydroxyethyl cellulose (HEC) and |
| |hydroxypropylmethyl cellulose (HPMC). They obtained convenient bioadhesion, acceptable elasticity, swelling and surface pH. They concluded that |
| |the mucoadhesive patches containing miconazole nitrate using anionic (SCMC), cationic (chitosan) and non-ionic (PVA, HEC, HPMC) polymers showed |
| |satisfactory mucoadhesive characteristics. Optimum release behaviour was shown with patches containing 10% w/v PVA and 5% w/v PVP. PVA patches |
| |improved uniform and effective miconazole levels in vitro and in vivo (>5 h) without being drastically influenced by ageing.14 |
| | |
| |Claudia Valenta (2004) gave a review on the use of mucoadhesive polymers in vaginal delivery. It stated that currently available dosage forms |
| |have several limitations, therefore novel concepts and dosage forms are needed. Mucoadhesive polymers play a major role. The anatomy and |
| |physiology of the vagina is discussed and highlights the most important studies based on mucoadhesive polymer-systems like poly (acrylates), |
| |chitosan, cellulose derivatives, hyaluronic acid derivatives, pectin and traganth, starch, poly(ethylene glycol), sulfated polysaccharides, |
| |carrageenan, Na-alginate and gelatine. According to the review mucoadhesive polymers are very promising candidates for systemic and local vaginal|
| |drug delivery. Most of the existing dosage forms are based on the synthetic pol (acrylates) but in the near future natural compounds such as |
| |chitosan or carrageenan and new derivatives will gain more significance15. |
| | |
| |Jung Y.C. et al., (2001) formulated clotrimazole (CT) in mucoadhesive thermosensitive gels (MTG) to develop more effective treatment for vaginal |
| |candidasis. They prepared Several MTG formulations composed of poloxamers (P) 407, 188, and polycarbophil (PC). Evaluated their mucoadhesive |
| |strength, did antifungal activity test, determined the work required to expel each formulation from a syringe, performed in vitro release |
| |studies, performed cellular viability studies and inoculated rats. Their results suggested that CT-containing vaginal MTG would be useful for |
| |effective and convenient for the treatment of vaginal candidasis with reduced dosing interval. And the cell viability and morphology data |
| |support the safety of MTG gels for vaginal application16. |
| | |
| |Rahamatullah S. et al., (2010) gave a detailed article on mucoadhesive drug delivery system. The review article aims to provide an overview of |
| |the various aspects of mucoadhesion, mucoadhesive materials, factors affecting mucoadhesion, evaluating methods, and finally various mucoadhesive|
| |drug delivery systems (buccal, nasal, ocular, gastro, vaginal, and rectal). They concluded that mucoadhesive dosage forms offer prolonged contact|
| |at the site of administration, low enzymatic activity, and patient compliance. The formulation of mucoadhesive drug delivery system depends on |
| |the selection of suitable polymer with excellent mucosal adhesive properties and biocompatibility17. |
| | |
| |Farhan J.A., (2008) developed an acid buffering bioadhesive vaginal (ABBV) gel for the treatment of mixed vaginal infections. Different |
| |bioadhesive polymers were evaluated on the basis of their bioadhesive strength, stability and drug release properties. The drugs clotrimazole |
| |(antifungal) and metronidazole (antiprotozoal as well as antibacterial) were used in the formulation along with Lactobacillus spores to treat |
| |infections. The developed bioadhesive gel was found to have prolonged ex vivo retention. The in vitro results of antimicrobial activity suggest |
| |that the acid buffering bioadhesive gel was more efficacious than the commercial formulation tested18. |
| | |
| |Jung Y.C et al., (2002).Formulated and evaluated various rheological properties of clotrimazole gels for predicting their performance in vagina. |
| |Two kinds of thermo sensitive and mucoadhesive formulations were composed of poloxamer 407 (P407, 15%), polycarbophil (0.2%), and different |
| |amounts of P188 (15 vs. 20%).Their steady shear behaviour,gelation temperature,gelation time, viscoelastic properties, dynamic mechanical |
| |analysis were obtained.The results indicated that the rheological evaluation at the physiologic conditions needs to be preceded to develop more |
| |effective in situ-gelling vaginal formulation and the difference in the composition of the thermosensitive and mucoadhesive gel formulations |
| |might lead to a dramatic change in the rheological behaviors. Results suggested that the rheological analysis in the physiological conditions |
| |would be a powerful tool for the prediction of gel behavior and drug efficacy after intravaginal application19. |
| | |
| |Constantia E. K., (2002) designed and evaluated a new bioadhesive vaginal drug delivery system for clotrimazole. Chitosan, a cationic biopolymer |
| |derived by deacetylation of chitin, was modified by the introduction of thioglycolic acid. The water uptake, dsintegration behavior, bioadhesive |
| |properties and the release of clotrimazole from were studied. Results showed that by the introduction of thiol groups the bioadhesive properties |
| |of chitosan could be significantly improved. The addition of clotrimazole further increased bioadhesion on mucosal tissue. The article concluded |
| |that the new chitosan–TGA conjugates are very promising vehicles for the vaginal application of clotrimazole in treatment of mycotic |
| |infections20. |
| | |
| |Esra B. et al., (2009) studied strategies to prolong the intravaginal residence time of drug delivery systems. Approaches for prolonging the |
| |residence time based on mucoadhesion, are in- situ sol-to-gel transition and mechanical fixation. An overview on mucoadhesive drug delivery |
| |systems and in-situ gelling systems for mechanical fixation is provided, the techniques to evaluate the potential of the systems for prolonged |
| |vaginal residence time are described and important polymers used in vaginal mucoadhesive gels are given21. |
| | |
| |A Madgulkar et al., (2009) developed buccal adhesive tablet of miconazole nitrate with prolonged antifungal activity and performed optimization |
| |and ex-vivo disposition studies. They also compared the formulation with the marketed gel. The drug concentrations above the minimum inhibitory |
| |concentration were achieved immediately from both formulations but the gel showed initially fast drug release. Drug permeation across buccal |
| |mucosa was minimum from both tablet as well as marketed gel22. |
| | |
| |Füsun A. (2009) gave a comprehensive review of the patents related to mucoadhesive vaginal drug delivery systems. Also confirmed that the vaginal|
| |route is appropriate for bioadhesive drug delivery systems in order to retain drugs. The article mentioned the most commonly used mucoadhesive |
| |polymers capable of forming hydrogels are synthetic polyacrylates, polycarbophil, chitosan, cellulose derivatives (hydroxyethycellulose, |
| |hydroxypropylcellulose and hydroxypropylmethylcellulose), hyaluronic acid derivatives, pectin, tragacanth, carrageenan and sodium alginate23. |
| | |
| |Ganure A.L. et al., (2011) in their abstract described the formulation and evaluation of gel containing chitosan (1%),various thickening agents |
| |like hydroxyethylcellulose (1%, w/w), sodium carboxy methyl cellulose (1%, w/w), hydroxy propyl cellulose (1%, w/w), methyl cellulose (1%, w/w), |
| |hydroxy propyl methyl cellulose (1% w/w), magnesium aluminum silicate (1%, w/w) and clotrimazole (1%, w/w) as a drug. The studies indicated that |
| |with increased concentrations of chitosan relative drug release were decreased. The study showed that chitosan (1%) and hydroxyl ethyl cellulose |
| |(6%) gel containing clotrimazole produced better spreadability and consistency as compared to marketed product and standard carbopol gel24. |
| |Phyllis L.C., et al., (1998) evaluated recent advances in understanding of clinical relevance, diagnosis and treatment of vaginal infections and |
| |determined an efficient and effective method of evaluating this problem. The study showed that use of topical therapies are effective and have |
| |lesser side effects as compared to the systemic medication. The study mentioned that for women with infrequent yeast vagintitis over the counter |
| |preparations of miconazole and clotrimazole for 7 days are appropriate treatments and should be used as first line therapy25. |
| | |
| |OBJECTIVE OF STUDY |
| | |
| |In the present research work an attempt will be made to formulate, optimize and evaluate antifungal vaginal hydrogel of miconazole. The gel will |
| |be prepared in order to increase the adhesion time of the drug at the site of application and hence to increase the permeation and bioavailabilty|
| |of the drug. |
| | |
| |SPECIFIC OBJECTIVES |
| | |
| |Screening of polymers for mucoadhesive hydrogel formulation |
| |To formulate optimized vaginal mucoadhesive hydrogel of miconazole nitrate |
| |To evaluate mucoadhesive hydrogel of miconazole nitrate for technological properties |
| |To study the in-vitro release of the developed formulation. |
| |To study ex-vivo bioadhesive strength by using fresh hairless goat skin |
| |To compare the in vitro release of the formulation with the present marketed preparation. |
| | |
| |Materials and Methods: |
| | |
| |7.1 Source of Data: |
| |1) Review of Literature from |
| |a) Journals - such as |
| |AAPS PharmSciTech. |
| |International Journal of Pharmaceutical Sciences |
| |Indian Journal of Pharmaceutical Sciences |
| |Pharmaceutical development and technology |
| |Science Direct. |
| |Pubmed |
| |Acta Pharm |
| |Journal of Applied Sciences Research |
| |Stamford Journal of Pharmaceutical Sciences |
| |b) Internet Browsing. |
| | |
| | |
| | |
| | |
| |7.2 - Method of Collection of Data: |
| |Literature survey |
| |Preformulation studies |
| |Standardization of method of estimation of miconazole nitrate |
| |Evaluation of drug excipients interaction by IR and DSC |
| |Screening of polymers (Chitosan, Sodium CMC, PVP,Carrageen,Agar and Guar Gum) for hydrogel formulation. |
| |Preparation of hydrogel of miconazole nitrate using selected polymers |
| |Evaluation of hydrogel for weight variation, drug content, content uniformity, swelling index, mucoadhesive strength and mucoadhesive time. |
| |Evaluation of rheological parameters. |
| |In-vitro release studies of prepared formulation and data analysis. |
| |To study ex-vivo bioadhesive strength by using fresh hairless goat skin |
| | |
| |7.3 - Does the study require any investigations or interventions to be conducted on patients or other humans or animals? If so, Please describe |
| |briefly. |
| |Not applicable |
| | |
| |7.4 – Has ethical clearance been obtained from your Institution in case of 7.3 |
| |Not applicable |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |Bibliography |
| | |
| |URL: (cited on 2012 march 7) |
| | |
| |URL: (cited on 2012 may 3) |
| | |
| |URL: (cited on 2012 march 8) |
| | |
| |URL: (cited on 2012 March 15) |
| | |
| |URL: (cited on 2012 may 1) |
| | |
| |Stephan WH. Suppositories.Biomaterials. 2002;535 |
| |URL: |
| | |
| |J. das Neves, M.F. Bahia. Gels as vaginal drug delivery systems. Int J Pharm. 2006;318:1-14 |
| | |
| |Krishna SV, Ashok V, Chatterjee A. A review on vaginal drug delivery systems. IJBPAS. 2012;1(2):152-167 |
| | |
| |Afaf A R. Formulation and evaluation of bioadhesive gels containing miconazole nitrate. J. Appl. Sci. Res. 2008;4(9):1052-1065 |
| | |
| |Tangri P, Madhav NVS. Oral mucoadhesive drug delivery systems: a review. Int J Biopharm. 2011;2(1):36-46. |
| | |
| |Amit A, Ajazuddin, Swarna, Mukesh S, D K Tripathi. Polymers and Permeation Enhancers: Specialized Components of Mucoadhesives. S. J. Pharm. Sci. |
| |2011;4(1):91-95 |
| | |
| |Pradeep K D, Joydeep D, V S Tripathi. Chitin and chitosan:Chemistry,properties and applications. J Sci Ind. 2004;63:20-31 |
| | |
| |Luana P, Valeria A, Lorena V, Cinzia P, Maurizio R, Carlo R. Chitosan and a modified chitosan as agents to improve performances of mucoadhesive |
| |vaginal gels. Biomaterials. 2008;66:141–145 |
| | |
| |Noha AN, Fatma A. Ismail, Nabila A. Boraie, Lobna MM. Mucoadhesive buccal patches of miconazole nitrate in vitro/in vivo performance and effect |
| |of ageing. Int. J. Pharm. 2003;264:1–14 |
| | |
| |Claudia V. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev. 2005;57:1692–1712 |
| | |
| |Jung YC, Yu-Kyoung O, Han-gon C, Yang BK, Chong-Kook K. Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels|
| |on vaginitis. J. Controlled Release. 2002;82:39–50 |
| | |
| |Rahamatullah S, Thakur RRS, Martin JG, A David W, Ryan FD. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89–100. |
| | |
| |Farhan JA, Mohd Aftab A, Zeenat I K, Roop KK, Mushir. Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed |
| |vaginal infections. Acta Pharm. 2008;5:407–419 |
| | |
| |Jung YC, Yu-Kyoung O, Han-gon C, Yang BK, Chong-Kook K. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological |
| |conditions. Int. J. Pharm. 2002:241:155–163 |
| | |
| |Constantia EK, Claudia V, Martina L, Andreas BS. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for |
| |clotrimazole. J. Controlled Release. 2002;81:347–354 |
| | |
| |Esra B, Zeynep AS, Sinem YK, Andreas BS. Strategies to Prolong the Intravaginal Residence Time of Drug Delivery Systems. J Pharm Pharmaceut Sci. |
| |2009;12(3):312–336 |
| | |
| |A Madgulkar, S Kadam, V Pokharkar. Development of buccal adhesive tablet with prolonged antifungal activity: Optimization and ex vivo deposition |
| |studies. Indian J Pharm Sci. 2009;71:290-4 |
| | |
| |Füsun A. Mucoadhesive Vaginal Drug Delivery Systems. Recent Patents on Drug Delivery & Formulation. 2009;3:193-205 |
| | |
| |Ganure AL, Patel PK, Dangi AA. Preparation and in-vitro evaluation of Chitosan loaded Clotrimazole Gel. IJPI’s JPC. 2011;1:2 |
| | |
| |Phyllis LC, Donna F, Robert HF. Evaluation and Management of Vaginitis. J Gen Intern Med. 1998;13:335-346 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|7.0 | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|8.0 | |
| | | |
| | | |
|9.0 |Signature of the Candidate |( BINISH KHAN) |
| | | |
|10.0 |Remarks of the Guide: |Recommended |
| | | |
|11.0 |Name and Designation of: | |
| | | |
| |11.1 Institutional Guide: |Dr. ROOPA S. PAI |
| | |Professor |
| | |Department of Pharmaceutics |
| | |Al-Ameen college of Pharmacy |
| | |Bangalore- 560 027 |
| | | |
| |11.2 Signature: | |
| | | |
| | |Dr. V. KUSUM DEVI |
| | |Professor and Head |
| |11.3 Head of the Department: |Department of Pharmaceutics |
| | |Al-Ameen College of Pharmacy |
| | |Bangalore- 560 027 |
| | | |
| |11.4 Signature: | |
| | | |
|12.0 |12.1 Remarks of the Chairman and Principal |Forwarded to the University for scrutiny |
| | | |
| | |Prof. B. G. SHIVANANDA |
| | |Principal |
| |12.2 Principal: |Al-Ameen College of Pharmacy, |
| | |Hosur Road, Bangalore – 560 027 |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- i tech international training and education center for
- candidiasis yeast infection
- rn study guide for preparing for the nln medication
- centers for disease control and prevention
- candida yeast infections and grapefruit seed extract
- rajiv gandhi university of health sciences
- medication or category rcampus
- university of central florida
- drugs for the reproductive system triton college
Related searches
- archives of biological sciences journal
- definition of social sciences pdf
- blackrock health sciences fact sheet
- list of social sciences degrees
- blackrock health sciences trust
- blackrock health sciences stock
- archives of biological sciences impact
- institute of mathematical sciences chennai
- university of natural health scam
- university of texas health system
- university of tampa health center
- university of medical sciences ondo